Effect of Atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-Week, Double-blind, Randomized, Phase 3 (PROGRESS) Trial for Preventive Treatment of Chronic Migraine

被引：0
|
作者：
Lipton, Richard B. [1 ]
Pozo-Rosich, Patricia [2 ,3 ]
Dodick, David W. [4 ]
Christie, Suzanne [5 ]
Ailani, Jessica [6 ]
Nagy, Krisztian [7 ]
Stokes, Jonathan [8 ]
Guo, Hua [8 ]
Gandhi, Pranav [8 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY USA
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Univ Autonoma Barcelona, Headache Res Grp, VHIR, Barcelona, Spain
[4] Mayo Clin, Dept Neurol, Scottsdale, AZ USA
[5] Univ Ottawa, Neurol, Ottawa, ON, Canada
[6] MedStar Georgetown Univ Hosp, Washington, DC USA
[7] AbbVie, Budapest, Hungary
[8] AbbVie, Madison, NJ USA
来源：
CEPHALALGIA | 2022年 / 42卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS22-PO-
引用
收藏
页码：87 / 89
页数：3
相关论文
共 32 条
  • [21] Daily dosing of atogepant for preventive treatment of migraine improved patient-reported outcomes measures of migraine-specific quality of life, activity impairment in migraine-diary, and headache-impact test in a 52-week trial
    Lipton, R. B.
    Singh, Halker R. B.
    Mechtler, L. L.
    McVige, J.
    Zhao, S.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Ashina, M.
    HEADACHE, 2021, 61 : 119 - 120
  • [22] Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial
    Goadsby, Peter J.
    Friedman, Deborah I.
    Holle-Lee, Dagny
    Demarquay, Genevieve
    Ashina, Sait
    Sakai, Fumihiko
    Neel, Brian
    Gandhi, Pranav
    Dabruzzo, Brett
    Smith, Jonathan H.
    Liu, Yingyi
    Trugman, Joel M.
    NEUROLOGY, 2024, 103 (02)
  • [23] Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 402, pg 775, 2023)
    Pozo-Rosich, P.
    Ailani, J.
    Ashina, M.
    LANCET, 2023, 402 (10410): : 1328 - 1328
  • [24] Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 402, pg 775, 2023)
    Pozo-Rosich, P.
    Ailani, J.
    Ashina, M.
    LANCET, 2023, 402 (10404): : 774 - 774
  • [25] A randomized, double-blind, placebo-controlled parallel trial to test the effect of inulin supplementation on migraine headache characteristics, quality of life and mental health symptoms in women with migraine
    Vajdi, Mahdi
    Khorvash, Fariborz
    Askari, Gholamreza
    FOOD & FUNCTION, 2024, 15 (19) : 10088 - 10098
  • [26] Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial (vol 103, e209584, 2024)
    Goadsby, Peter J.
    Friedman, Deborah, I
    Holle-Lee, Dagny
    Demarquay, Genevieve
    Ashina, Sait
    Sakai, Fumihiko
    Neel, Brian
    Gandhi, Pranav
    Dabruzzo, Brett
    Smith, Jonathan H.
    Liu, Yingyi
    Trugman, Joel M.
    NEUROLOGY, 2024, 103 (10)
  • [27] Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
    Lipton, Richard B.
    Tepper, Stewart J.
    Silberstein, Stephen D.
    Kudrow, David
    Ashina, Messoud
    Reuter, Uwe
    Dodick, David W.
    Zhang, Feng
    Rippon, Gregory A.
    Cheng, Sunfa
    Mikol, Daniel D.
    CEPHALALGIA, 2021, 41 (01) : 6 - 16
  • [28] Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study
    Quigley, E. M. M.
    Vandeplassche, L.
    Kerstens, R.
    Ausma, J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (03) : 315 - 328
  • [29] Impact of fremanezumab on migraine-specific quality of life in patients with medication overuse and documented inadequate response to 2-4 classes of migraine preventive treatments: subgroup analysis of the international, multicentre, randomised, double-blind FOCUS study
    Mechtler, Laszlo
    Ramirez-Campos, Verena
    Cohen, Joshua M.
    Janka, Lindsay
    CEPHALALGIA, 2019, 39 : 221 - 221
  • [30] Botulinum neurotoxin type A treatment improves health-related quality of life and reduces the impact of chronic migraine: results from the double-blind phase of the PREEMPT clinical program
    Lipton, R. B.
    Varon, S.
    Grosberg, B.
    McAllister, P. J.
    Freitag, F.
    DeGryse, R. E.
    Turkel, C. C.
    CEPHALALGIA, 2009, 29 : 32 - 33
1234